534 related articles for article (PubMed ID: 19722231)
1. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
Ren DN; Kim IY; Koh SB; Chang SJ; Eom M; Yi SY; Seong SH; Kim MD; Bronner MP; Cho MY
J Surg Oncol; 2009 Dec; 100(7):546-52. PubMed ID: 19722231
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
3. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
Merkelbach-Bruse S; Hans V; Mathiak M; Sanguedolce R; Alessandro R; Rüschoff J; Büttner R; Houshdaran F; Gullotti L
Oncol Rep; 2004 Apr; 11(4):839-43. PubMed ID: 15010882
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
[TBL] [Abstract][Full Text] [Related]
5. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.
Ishida Y; Kawakami K; Tanaka Y; Kanehira E; Omura K; Watanabe G
Anticancer Res; 2002; 22(5):2805-9. PubMed ID: 12530000
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
7. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
Mauritz R; Giovannetti E; Beumer IJ; Smid K; Van Groeningen CJ; Pinedo HM; Peters GJ
Clin Colorectal Cancer; 2009 Jul; 8(3):146-54. PubMed ID: 19632929
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
11. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E
Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121
[TBL] [Abstract][Full Text] [Related]
12. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J
Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
14. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
16. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
Wong NA; Brett L; Stewart M; Leitch A; Longley DB; Dunlop MG; Johnston PG; Lessells AM; Jodrell DI
Br J Cancer; 2001 Dec; 85(12):1937-43. PubMed ID: 11747337
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
Hu YC; Komorowski RA; Graewin S; Hostetter G; Kallioniemi OP; Pitt HA; Ahrendt SA
Clin Cancer Res; 2003 Sep; 9(11):4165-71. PubMed ID: 14519641
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival.
Tanaka-Nozaki M; Tajiri T; Tanaka N; Furukawa K; Takasaki H; Yoshimura K; Suzuki H; Naito Z; Sugizaki Y; Merk HF; Blömeke B; Kato S
Oncol Rep; 2003; 10(5):1425-9. PubMed ID: 12883718
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients.
Kuramochi H; Tanaka K; Oh D; Lehman BJ; Dunst CM; Yang DY; De Meester SR; Hagen JA; Danenberg KD; De Meester TR; Danenberg PV
Int J Oncol; 2008 Jan; 32(1):201-8. PubMed ID: 18097560
[TBL] [Abstract][Full Text] [Related]
20. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma.
Gertler R; Rosenberg R; Stricker D; Werner M; Lassmann S; Ulm K; Nekarda H; Siewert JR
Cancer; 2002 Nov; 95(10):2103-11. PubMed ID: 12412163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
